Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in
patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled,
superiority trial. Tamiru Shibiru Degaga, Ayodhia Pitaloka Pasaribu, Rupam Tripura, Najia Ghanchi, Megha Rajasekhar,
Bipin Adhikari, Benedikt Ley, Samuel Alemu Bamboro, Fareeha Abdul Jabbar, Nurfadhilah Hasibuan, Tedla Teferi Tego,
Shane Zehra, Bushra Qurashi, Hellen Mnjala, Grant Lee, Peixuan Li, Abdul Momin Kazi, Widaya Safitri, Yulita Yulita, Dedi
Sahat Parningotan Siagian, Deni Syahputra, Halik Hadi, Taj Muhammad, Amna Ibrahim, Nasreen Syed, Khuda Dost, Agatha Mia Puspitrasari, Pinkan Pertiwi Kariodimedjo, Anjana Rai, Angela Rumaseb, Edwin Sutanto, Mom Ean, Asia Khan, Meas Sokha, Robert James Commons, Sophie Weston, Rintis Noviyanti, Tom Peto, James J Callery, Umair Ali, Tariq Mehmood, Arjen Dondorp, Angela Devine, Ery Setiawan, Muthoni Mwaura, Sarah Cassidy-Seyoum, Rodas Temesgen, Dagimawie Tadesse Abate, Eyerusalem Beyene Erjabo, Geremew Gashaw Gessa, Fitsum Getahun Kiros, Muhammad Imran Usmani, Ali Raza, Adugna Woyessa, Asrat Hailu, Julie A Simpson, Amalia Karahalios, Mohammad Asim Beg, Lorenz von Seidlein, Lek Dysoley, Sarah Auburn, Ric N Price, Kamala Thriemer, https://doi.org/10.1016/S1473-3099(25)00729-7, https://pubmed.ncbi.nlm.nih.gov/41690325/.